FY2025 EPS Estimates for ABOS Reduced by Cantor Fitzgerald

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) – Cantor Fitzgerald reduced their FY2025 earnings estimates for Acumen Pharmaceuticals in a note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings of ($1.92) per share for the year, down from their prior forecast of ($1.84). The consensus estimate for Acumen Pharmaceuticals’ current full-year earnings is ($1.56) per share.

Several other analysts have also recently weighed in on the stock. HC Wainwright decreased their price objective on shares of Acumen Pharmaceuticals from $15.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, March 28th. UBS Group decreased their price objective on shares of Acumen Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, March 28th.

Acumen Pharmaceuticals Price Performance

Shares of Acumen Pharmaceuticals stock opened at $1.07 on Monday. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $64.81 million, a price-to-earnings ratio of -0.78 and a beta of 0.09. Acumen Pharmaceuticals has a 1-year low of $0.86 and a 1-year high of $3.92. The firm’s 50-day moving average price is $1.08 and its two-hundred day moving average price is $1.59.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.08. During the same quarter in the prior year, the firm earned ($0.25) EPS.

Institutional Trading of Acumen Pharmaceuticals

Several hedge funds have recently modified their holdings of ABOS. JPMorgan Chase & Co. grew its stake in shares of Acumen Pharmaceuticals by 1,387.2% during the fourth quarter. JPMorgan Chase & Co. now owns 937,908 shares of the company’s stock valued at $1,613,000 after purchasing an additional 874,842 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Acumen Pharmaceuticals by 116.1% during the fourth quarter. Jane Street Group LLC now owns 30,740 shares of the company’s stock valued at $53,000 after purchasing an additional 221,144 shares during the last quarter. Invesco Ltd. grew its stake in shares of Acumen Pharmaceuticals by 544.1% during the first quarter. Invesco Ltd. now owns 127,798 shares of the company’s stock valued at $141,000 after purchasing an additional 107,956 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Acumen Pharmaceuticals during the fourth quarter valued at approximately $162,000. Finally, Deutsche Bank AG grew its stake in shares of Acumen Pharmaceuticals by 468.7% during the fourth quarter. Deutsche Bank AG now owns 96,995 shares of the company’s stock valued at $167,000 after purchasing an additional 79,940 shares during the last quarter. 71.01% of the stock is owned by institutional investors.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.